Current Opinion in Immunology最新文献_第5页

The impact of viral evolution on vaccine development for SARS-CoV-2 病毒进化对SARS-CoV-2疫苗研制的影响

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-18 DOI: 10.1016/j.coi.2025.102612

Martin F Bachmann , Mona O Mohsen , Daniel E Speiser

引用次数: 0

Metabolic regulation of the immune cell in psoriasis: mechanisms and interventions 银屑病免疫细胞的代谢调节：机制和干预

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-16 DOI: 10.1016/j.coi.2025.102614

Dan Hong , Hui Xiong , Siyao Lu , Jianchi Ma , Zhenrui Shi

引用次数: 0

Insights into platelet post-transfusional human leukocyte antigen I immunization 血小板输注后人白细胞抗原I免疫的研究进展

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-16 DOI: 10.1016/j.coi.2025.102607

Gabriel Rojas-Jiménez, Blandine Maître

引用次数: 0

HLA-B27 as a potential target for the cure of axial spondyloarthritis HLA-B27作为治疗轴性脊柱炎的潜在靶点

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-16 DOI: 10.1016/j.coi.2025.102611

Carlo Cannistrà , Suraj Timilsina , Merrill Eric Gershwin , Carlo Selmi

{"title":"HLA-B27 as a potential target for the cure of axial spondyloarthritis","authors":"Carlo Cannistrà , Suraj Timilsina , Merrill Eric Gershwin , Carlo Selmi","doi":"10.1016/j.coi.2025.102611","DOIUrl":"10.1016/j.coi.2025.102611","url":null,"abstract":"<div><div>Axial spondyloarthritis (axSpA) manifests with inflammatory back pain and is diagnosed predominantly in subjects carrying the human leucocyte antigen (HLA)-B27 allele. While not diagnostic for the disease or a predictive biomarker in the general population, there is convincing data on the pathogenic role of HLA-B27 in axSpA via different proinflammatory mechanisms. Similar to other chronic conditions, axSpA requires lifelong treatments, including biologics and small molecules, to treat inflammation and ultimately halt disease progression by achieving sustained disease remission. There is currently no cure for axSpA, but one fascinating thesis is that gene therapy may hold the potential to reverse the disease. We provide herein a comprehensive and critical review of the advances in gene therapy strategies, including gene-editing techniques, RNA interference, and viral vector–mediated delivery systems, with a focus on the possible future developments in HLA-B27-related mechanisms. Understanding these novel approaches may pave the way for more effective, personalized treatments capable of solving the HLA-B27-positive axSpA conundrum.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102611"},"PeriodicalIF":6.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we cure autoimmune hepatitis? 我们能治愈自身免疫性肝炎吗？

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-14 DOI: 10.1016/j.coi.2025.102609

Maria Serena Longhi , Lina Zhang , Giorgina Mieli-Vergani , Diego Vergani

{"title":"Can we cure autoimmune hepatitis?","authors":"Maria Serena Longhi , Lina Zhang , Giorgina Mieli-Vergani , Diego Vergani","doi":"10.1016/j.coi.2025.102609","DOIUrl":"10.1016/j.coi.2025.102609","url":null,"abstract":"<div><div>Autoimmune hepatitis (AIH) is an organ-specific autoimmune disorder mainly affecting females and characterized by seropositivity for autoantibodies, hypergammaglobulinemia, and histological evidence of interface hepatitis. Liver damage in AIH is perpetrated by multiple immune cell subsets, including B, T lymphocytes, and macrophages. Dysfunction of regulatory T cells (Tregs), an immune subset central to immunotolerance, plays an important permissive role by enabling effector lymphocytes to act unopposed and perpetuate autoimmune liver injury. Corticosteroids and azathioprine are the mainstay of treatment, resulting in disease remission in 80–90% of cases. Second- and third-line treatment, including mycophenolate mofetil, calcineurin inhibitors, and anti-B lymphocyte strategies, are used in difficult-to-treat cases or intolerant patients. Although controlling inflammation, these immunosuppressants are associated with significant side effects that impact patients’ quality of life and adherence to treatment and, importantly, do not enable immune tolerance reconstitution. Strategies based on adoptive transfer of or <em>ex vivo</em> expansion of Tregs would enable limiting effector cell immunity while reconstituting immune tolerance. Additional studies into the mechanisms resulting in Treg dysfunction at both systemic and tissue levels are warranted to engineer more potent, stable, and long-lasting Tregs to be used in immunotherapy. Restoring Treg pool would be a key step forward toward the cure of this autoimmune condition and other autoimmune diseases with similar pathogenesis.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102609"},"PeriodicalIF":6.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping economic outcomes: how biosimilars enhance access to health systems in Latin America and the Caribbean 绘制经济成果：生物仿制药如何促进拉丁美洲和加勒比卫生系统的可及性

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-10 DOI: 10.1016/j.coi.2025.102606

María Herrán , Juan-Manuel Anaya

引用次数: 0

Moving beyond the Janus kinase signaling kinases in the pathogenesis and treatment of psoriasis and psoriatic arthritis 超越Janus激酶信号激酶在银屑病和银屑病关节炎的发病和治疗中的作用

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-07 DOI: 10.1016/j.coi.2025.102601

Smriti K Raychaudhuri , Disha Chakraborty , Christopher L Leonardini , Siba P Raychaudhuri

{"title":"Moving beyond the Janus kinase signaling kinases in the pathogenesis and treatment of psoriasis and psoriatic arthritis","authors":"Smriti K Raychaudhuri , Disha Chakraborty , Christopher L Leonardini , Siba P Raychaudhuri","doi":"10.1016/j.coi.2025.102601","DOIUrl":"10.1016/j.coi.2025.102601","url":null,"abstract":"<div><div>Psoriatic disease encompasses psoriasis and psoriatic arthritis. It is a chronic, progressive condition and leads to irreversible joint destruction. Conventional treatments used are disease-modifying antirheumatic drugs and biologics. Janus kinase (JAK) signal transducers and activators of transcription (STAT) cell signaling protein inhibitors have shown promising results in psoriatic disease. However, JAK inhibitors have been associated with some concerning safety issues, such as cardiac risks, venous thrombotic episodes, malignancy, and infection. There are other developing molecules beyond JAK inhibitors, such as tyrosine kinase 2 (TYK2) inhibitors, RAR-related orphan receptor gamma (RORγ) inhibitors, mammalian target of rapamycin inhibitors, nerve growth factor inhibitors, and STAT kinase inhibitors. In this narrative review, we have discussed such molecular targets beyond JAK inhibitors to examine their role in the treatment of psoriatic disease. This review discusses the potential of these new options, particularly TYK2 inhibitors, which is already Food and Drug Administration approved for psoriasis. These advancements offer promising options for the management of psoriatic disease.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"95 ","pages":"Article 102601"},"PeriodicalIF":6.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease 双重免疫抑制剂治疗耐药银屑病的概念

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-07 DOI: 10.1016/j.coi.2025.102602

Disha Chakraborty , Siba P Raychaudhuri

{"title":"Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease","authors":"Disha Chakraborty , Siba P Raychaudhuri","doi":"10.1016/j.coi.2025.102602","DOIUrl":"10.1016/j.coi.2025.102602","url":null,"abstract":"<div><div>Biologic therapies have significantly improved the management of immune-mediated conditions like psoriatic disease, enhancing the quality of life of patients. However, monotherapy is often insufficient, especially in cases of relapse, concomitant psoriatic arthritis, and involvement of difficult-to-treat areas: the scalp, palmoplantar areas, inverse regions, or genital areas. Patients with psoriatic disease also exhibit varying responses in their skin and joint manifestations to the same biologic, making dual biologic therapy a potential solution. Psoriasis is increasingly recognized as a systemic disease affecting multiple organs, and given the complex pathophysiology, different organs may respond differently to treatment. Targeting multiple immune mediators simultaneously could therefore lead to more effective disease control. Common combinations include TNF inhibitors with IL-17/23 antagonists. Despite its potential, dual biologic therapy remains infrequent, with most data coming from clinical case reports. This review explores dual immune inhibition as a therapeutic strategy, its rationale, and limitations for drug-resistant psoriatic disease.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"95 ","pages":"Article 102602"},"PeriodicalIF":6.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of epigenetic modifications in systemic autoinflammatory diseases 表观遗传修饰在系统性自身炎症疾病中的作用

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-05 DOI: 10.1016/j.coi.2025.102599

Kader Cetin Gedik , Desiré Casares-Marfil , Erkan Demirkaya , Amr H Sawalha

{"title":"The role of epigenetic modifications in systemic autoinflammatory diseases","authors":"Kader Cetin Gedik , Desiré Casares-Marfil , Erkan Demirkaya , Amr H Sawalha","doi":"10.1016/j.coi.2025.102599","DOIUrl":"10.1016/j.coi.2025.102599","url":null,"abstract":"<div><div>Autoinflammatory diseases are a group of immune dysregulation disorders, with genetic mutations identified in approximately 50% of patients. However, patients with known pathogenic mutations may display a broad range of phenotypic diversity. Epigenetic modifications play a crucial role in regulating immune-mediated diseases, including autoinflammatory diseases, influencing disease course and complications. This review provides an overview of the current literature on the role of epigenetic changes in autoinflammatory diseases, examining their implications for disease mechanisms. To identify biological processes and pathways influenced by microRNAs across autoinflammatory diseases, we performed enrichment analyses in Gene Ontology biological processes. This analysis revealed enriched pathways reflecting the varying biological mechanisms implicated in familial Mediterranean fever (FMF), tumor necrosis factor associated periodic syndrome (TRAPS), and neonatal-onset multisystem inflammatory disease (NOMID). Notably, FMF was linked to clinically significant pathways, including those related to cytokine production, cardiovascular system, and neuroinflammation. These results highlight the potential of epigenetic modifications as biomarkers for autoinflammatory diseases. Given the role of epigenetic modifications in gene expression and the growing interest in their involvement in disease pathogenesis and therapy, including in rare disorders, further research into the epigenetic landscape of autoinflammatory diseases is essential. Furthermore, integrating genetic, epigenetic, and environmental factors will be key to addressing clinical variability and developing personalized treatment approaches.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"95 ","pages":"Article 102599"},"PeriodicalIF":6.6,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and consequences of red blood cell autoantibodies: warm autoimmune hemolytic anemia 红细胞自身抗体的发展和后果：温热自身免疫性溶血性贫血

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-04 DOI: 10.1016/j.coi.2025.102604

Flavia Dei Zotti , Krystalyn E Hudson

引用次数: 0